Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A real-life study to determine role of resistance-associated substitutions to direct-acting-antivirals in patients with hepatitis C virus genotype 3 within the Italian VIRONET-C network

Next Previous
Trial Profile

A real-life study to determine role of resistance-associated substitutions to direct-acting-antivirals in patients with hepatitis C virus genotype 3 within the Italian VIRONET-C network

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daclatasvir/sofosbuvir (Primary) ; Dasabuvir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Ledipasvir (Primary) ; Ombitasvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Ritonavir (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Velpatasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use

Most Recent Events

  • 20 Aug 2021 Status changed from not stated to completed.
  • 18 Aug 2021 New trial record
  • 01 Aug 2021 Results published in the Liver International

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top